摘要
目的探讨分析恩替卡韦联合苦参素片治疗HBeAg阳性慢性乙型肝炎的临床疗效。方法将110例HBeAg阳性慢性乙型肝炎患者随机分为观察组(55例)和对照组(55例),观察组患者给予恩替卡韦联合苦参素片进行治疗。对照组患者仅给予恩替卡韦进行治疗,治疗48周后,观察两组患者的临床有效率,记录两组患者谷丙酸转氨酶(ALT)复常率、HBV-DNA转阴率、HBeAg/HBeAb血清转换率以及治疗前后两组患者肝纤维化指标变化和不良反应发生情况。结果经过48周的治疗后,观察组患者的ALT复常率、HBV-DNA转阴率以及HBeAg/HBeAb血清转换率均显著高于对照组,差异有统计学意义(P<0.05);治疗后患者的HA、LN和PCⅢ等肝纤维化指标均优于治疗前,治疗后观察组患者的以上肝纤维化指标显著优于对照组,差异有统计学意义(P<0.05);治疗过程中患者均无严重的不良反应情况发生。结论恩替卡韦联合苦参素片治疗HBeAg阳性慢性乙型肝炎具有较好的临床疗效,有效地抑制乙型肝炎病毒复制,且临床治疗中无明显的不良反应的发生,安全性高。
Objective To explore the clinical efficacy of entecavir combined with matrine tablets on patients with HBeAg positive chronic hepatitis B. Methods Totally 110 patients with HBeAg positive chronic hepatitis B were selected in our hospital, and they were ran- domly divided into the observation group （55 cases） and the control group （55 cases）. The observation group was treated with entecavir combined with matrine tablets, and the control group was only given entecavir alone. After the treatment of 48 weeks, the clinical efficacy, alanine aminotransferase （ALT） normalization, HBV - DNA transfer negative rate, HBeAg/HBeAb seroconversion rate, the changes in liver fibrosis before and after treatment, and the adverse reactions of the two groups were observed. Results After 48 weeks of treatment, ALT normalization, HBV - DNA transfer negative rate, HBeAg/HBeAb seroconversion rate of the observation group were significantly higher than those of the control group, and the difference was statistically significant （P 〈 0.05） ; after treatment, HA, LN and PC III and other liver fibrosis indicators were better than before ; these indicators of the observation group were significantly better than those of the control group after treatment, and the difference was statistically significant （P 〈 0.05） All the patients had no significant adverse reactions during treatment. Conclusion The treatment of entecavir combined with matrine tablets on patients with HBeAg positive chronic hepatitis B has better clinical efficacy, which can suppress HBV replication very effectively w^thout significant adverse reactions.
出处
《安徽医学》
2013年第9期1314-1316,共3页
Anhui Medical Journal
